A particular feature of non-specific bronchial hyper-reactivity is represented by EIA, that is a very suitable model for the study of drugs for treatment of patients with bronchial asthma. Therefore, according to a randomized design, we submitted a hundred asthmatics, EIA positive (65 males and 35 females; mean age 19.8±10.2 years), to three same standardized exercise challenges with prior administration of salbutamol, disodium cromoglycate and ipratropium bromide. No treatment was given for 24 hours before each exercise challenge. At baseline and during the recovery period, between the 5th and the 10th minute, FEV1.0 and sGaw were assessed. Mean baseline values of FEV1.0 were 96.6%, 95.5%, 95.4% and 94.8% of predicted mean age specific one for the baseline and the three protected challenges respectively, without statistical differences (F=0.397, NS). The trend of FEV1.0 showed a significant difference (F =28.9, p1.0 as criterion salbutamol could prevent EIA in 89% of the patients, disodium cromoglycate in 81% and ipratropium bromide in 62%. These data are confirmed by sGaw behaviour.
|Translated title of the contribution||Pharmacologic prevention of exercise-induced asthma|
|Number of pages||6|
|Publication status||Published - 1985|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine